China Chemical & Pharmaceutical Co Ltd
TWSE:1701
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (14.3), the stock would be worth NT$21.72 (3% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.9 | NT$21.15 |
0%
|
| 3-Year Average | 14.3 | NT$21.72 |
+3%
|
| 5-Year Average | 13.9 | NT$21.15 |
0%
|
| Industry Average | 12.6 | NT$19.13 |
-10%
|
| Country Average | 14.3 | NT$21.72 |
+3%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
C
|
China Chemical & Pharmaceutical Co Ltd
TWSE:1701
|
6.3B TWD | 13.9 | 17.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.6 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.1 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.6 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 10.4 |
| Median | 14.3 |
| 70th Percentile | 23.6 |
| Max | 8 048.6 |
Other Multiples
China Chemical & Pharmaceutical Co Ltd
Glance View
China Chemical & Pharmaceutical Co., Ltd. engages in the business of buying, selling, manufacturing, importing, and exporting pharmaceutical products. The company is headquartered in Taipei City, Taipei. The products of the Company include pharmaceuticals for human, animal drugs, medical devices, daily products and nutritious food products. Pharmaceuticals for human include prescription drugs and patented medicines, among others. Medical equipment includes nursing liquid for contact lens, sphygmomanometers and manmade joints. Animal drugs include feedstuff additives and healthcare products for animals, among others. Daily products include toothpastes, shower liquid, facial masks and mouth rinses, among others. The firm operates businesses in Taiwan and Mainland China.
